News | Webinars | Publications | Conferences | Upcoming Events |
-
November 22, 2022
Why the TAAR1 agonist ulotaront holds promise for schizophrenia -
November 10, 2022
A novel phenotypic approach to CNS drug discovery -
October 24, 2022
4 next-gen CNS drug development trends -
October 12, 2022
Why Psychogenics and Emyria are collaborating to examine MDMA-inspired compounds -
October 11, 2022
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics -
September 22, 2022
Emyria starts program with neuroscience drug discovery CRO -
September 22, 2022
Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More -
September 21, 2022
Emyria teams with CRO PsychoGenics for MDMA-like drug development -
August 24, 2022
Overcoming mental health’s drug development challenges with AI
